Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $692.000 thousand which missed the analyst consensus estimate of $3.998 million by 82.69 percent. This is a 97.60 percent decrease over sales of $28.866 million the same period last year.